Allogene Therapeutics Inc (ALLO)
US Market

Allogene Therapeutics (ALLO) Financial Statements


Allogene Therapeutics Financial Overview

Allogene Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.79; its P/E ratio is -1.41; Allogene Therapeutics is scheduled to report earnings on August 7, 2024, and the estimated EPS forecast is $-0.35. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue$ -44.00K$ 43.00K$ 44.00K$ 52.00K$ 47.00K
Gross Profit$ -44.00K$ 43.00K$ 44.00K$ 52.00K$ 47.00K
EBIT$ -89.21M$ -61.31M$ -77.99M$ -98.70M$ -98.10M
EBITDA$ -85.73M$ -57.74M$ -74.35M$ -95.20M$ -95.03M
Net Income Common Stockholders$ -89.26M$ -61.31M$ -77.99M$ -98.70M$ -94.85M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 448.70M$ 465.50M$ 491.96M$ 471.22M$ 517.32M
Total Assets$ 642.84M$ 712.33M$ 770.97M$ 746.87M$ 817.06M
Total Debt$ 88.35M$ 90.10M$ 91.82M$ 93.51M$ 95.12M
Net Debt$ -360.35M$ -375.40M$ -400.14M$ -377.71M$ -422.20M
Total Liabilities$ 130.60M$ 129.22M$ 148.06M$ 154.61M$ 1.22B
Stockholders Equity$ 512.23M$ 583.10M$ 622.91M$ 592.26M$ 1.07B
Cash Flow-
Free Cash Flow$ -53.89M$ -55.54M$ -62.15M$ -67.67M$ -63.79M
Operating Cash Flow$ -53.71M$ -55.53M$ -61.86M$ -66.64M$ -62.10M
Investing Cash Flow$ 67.46M$ -34.27M$ 17.16M$ 112.94M$ 49.60M
Financing Cash Flow$ 155.00K$ 4.29M$ 89.52M$ 1.73M$ 46.00K
Currency in USD

Allogene Therapeutics Earnings and Revenue History

Allogene Therapeutics Debt to Assets

Allogene Therapeutics Cash Flow

Allogene Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis